MicroHealth
MicroHealth is a healthcare company based in New York, NY, specializing in consumer health and wellness, with a mission to advance hematology through digital tools. Founded in 2015 as part of Y Combinator's S15 batch, the company supports clients like Biogen and Sanofi and offers mobile applications for hemophilia and sickle cell disease.
Company Overview
MicroHealth is a healthcare company launched in 2015 as part of the Y Combinator S15 batch. The company focuses on consumer health and wellness, operating in the healthcare sub-industry. With a team size of 9, MicroHealth has locations in New York, NY, USA, and supports remote work.
Mission and Guiding Principles
MicroHealth's mission is to advance hematology by building digital tools that add clinical and economic value. The company's guiding principles include doing what is good for the patient, moving the health outcomes needle, and building digital tools with a human touch.
Digital Therapeutics and Networks
MicroHealth develops digital therapeutics to address unmet medical needs in hematology and oncology. The company builds networks of doctors and patients to track, predict, and prevent disease. They validate the safety and efficacy of their interventions in pivotal clinical studies to obtain regulatory clearance for Software as a Medical Device (SaMD). Their hemophilia network covers 33% of all patients and providers in the U.S.
Products and Services
MicroHealth offers a range of products for patients, providers, and pharmaceutical companies. These include engagement and adherence tools, research and study support, and AI algorithms and interventions. The company provides mobile applications for Hemophilia and Sickle Cell Disease available on iOS and Android platforms. A 'coming soon' section indicates that offerings for Blood Cancers are in development.
Clients and Partnerships
MicroHealth supports high-profile clients including Biogen, Shire, Bayer, Roche, and Sanofi. Their digital health solutions cater to both patients and healthcare providers, emphasizing engagement and adherence. The company aims to commercialize their products as prescription digital therapeutics (DTx) to achieve broader clinical use.